HRP20120652T1 - Organski spojevi - Google Patents
Organski spojevi Download PDFInfo
- Publication number
- HRP20120652T1 HRP20120652T1 HRP20120652TT HRP20120652T HRP20120652T1 HR P20120652 T1 HRP20120652 T1 HR P20120652T1 HR P20120652T T HRP20120652T T HR P20120652TT HR P20120652 T HRP20120652 T HR P20120652T HR P20120652 T1 HRP20120652 T1 HR P20120652T1
- Authority
- HR
- Croatia
- Prior art keywords
- staurosporine
- benzoyl
- crystalline form
- solution
- compound
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims abstract 13
- 150000001875 compounds Chemical class 0.000 claims abstract 11
- 238000002441 X-ray diffraction Methods 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- 239000002244 precipitate Substances 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 claims 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 238000000862 absorption spectrum Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Extraction Or Liquid Replacement (AREA)
- Peptides Or Proteins (AREA)
Abstract
Spoj, naznačen time, da je to kristalni oblik II od N-benzoil-staurosporina, koji ima uzorak difrakcije X-zraka, izra·en u razmacima od 2-teta vrijednosti, koji uključuje pet ili vi®e vr®nih vrijednosti odabrane iz skupine koju čine oko 3,4, 6,0, 7,8, 8,7, 9,2, 9,7, 10,1, 10,4, 11,2, 12,6, 14,1, 15,7, 16,8, 18,2, 18,9, 19,3, 19,6, 20,2 i 24,5 ą 0,2 stupnjeva. Patent sadr·i jo® 16 patentnih zahtjeva.
Claims (17)
1. Spoj, naznačen time, da je to kristalni oblik II od N-benzoil-staurosporina, koji ima uzorak difrakcije x-zraka, izražen u razmacima od 2-teta vrijednosti, koji uključuje pet ili više vršnih vrijednosti odabrane iz skupine koju čine oko 3,4, 6,0, 7,8, 8,7, 9,2, 9,7, 10,1, 10,4, 11,2, 12,6, 14,1, 15,7, 16,8, 18,2, 18,9, 19,3, 19,6, 20,2 i 24,5 ± 0,2 stupnjeva.
2. Spoj prema zahtjevu 1, naznačen time, da ima uglavnom isti uzorak difrakcije X-zraka kao što je prikazano u Slici 1.
3. Spoj prema zahtjevu 1, naznačen time, da ostaje suh na 95% relativne vlažnosti i na 25°C.
4. Spoj prema zahtjevu 1, naznačen time, da ima spektar infracrvene apsorpcije s apsorpcijskim opsegom na oko 789, 773, 743, 704, 1066, 1026, 1458, 1398, 1383, 1602, 1577, 1497, 1627, 1680, 2934 i 3055 cm-1± 2 cm-1.
5. Spoj, naznačen time, da sadrži N-benzoil-staurosporin kao krutinu, pri čemu je najmanje 80 masenih % od spomenute krutine N-benzoil-staurosporina u kristalnom obliku II prema zahtjevu 1.
6. Spoj prema zahtjevu 5, naznačen time, da pri čemu je najmanje 90 masenih % od spomenute krutine N-benzoil-staurosporina u kristalnom obliku II.
7. Spoj prema zahtjevu 5, naznačen time, da pri čemu je najmanje 95 masenih % od spomenute krutine N-benzoil-staurosporina u kristalnom obliku II.
8. Farmaceutski sastav, naznačen time, da sadrži:
(a) spoj prema zahtjevu 1; i
(b) farmaceutski prihvatljiv nosač ili razrjeđivač.
9. Farmaceutski sastav prema zahtjevu 8, naznačen time, da nadalje sadrži jedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
10. Farmaceutski sastav prema zahtjevu 8, naznačen time, da je u dozirnom obliku pogodnom za oralnu primjenu.
11. Farmaceutski sastav prema zahtjevu 10, naznačen time, da je spomenuti dozirni oblik odabran od tablete, kapsule ili otopine.
12. N-benzoil-staurosporin prema bilo kojem od zahtjeva 1 do 8, naznačen time, da je za uporabu u liječenju tumorskih bolesti.
13. Postupak proizvodnje kristalnog oblika II od N-benzoil-staurosporina prema zahtjevu 1, naznačen time, da obuhvaća:
(a) pribavljanje otopine N-benzoil-staurosporina u otapalu;
(b) stavljanje u doticaj otopine s drugim otapalom za stvaranje taloga; i
(c) izoliranje taloga; pri čemu otapalo je odabrano od sljedećih: benzilni alkohol, DMF, DMSO, octena kiselina ili PEG; pri čemu je drugo otapalo odabrano od sljedećih: etanol, THF ili otopina etanola i vode.
14. Postupak prema zahtjevu 13, naznačen time, da nadalje obuhvaća sušenje izoliranog taloga.
15. Spoj, naznačen time, da je to kristalni oblik II od N-benzoil-staurosporina proizveden postupkom iz zahtjeva 13.
16. Postupak proizvodnje kristalnog oblika II od N-benzoil-staurosporina iz zahtjeva 1, naznačen time, da obuhvaća:
(a) reagiranje staurosporina s anhidridom benzoične kiseline za tvorbu otopine;
(b) kultiviranje otopine s kristalnim oblikom II od N-benzoil-staurosporina;
(c) dodavanje drugog otapala; i
(d) izoliranje proizvoda; pri čemu je drugo otapalo odabrano od etanola ili otopine etanola i vode.
17. Spoj, naznačen time, da je to kristalni oblik II od N-benzoil-staurosporina proizveden postupkom iz zahtjeva 16.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62534304P | 2004-11-05 | 2004-11-05 | |
| US64213105P | 2005-01-07 | 2005-01-07 | |
| PCT/EP2005/011789 WO2006048296A1 (en) | 2004-11-05 | 2005-11-03 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120652T1 true HRP20120652T1 (hr) | 2012-09-30 |
Family
ID=35501294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120652TT HRP20120652T1 (hr) | 2004-11-05 | 2012-08-10 | Organski spojevi |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8198435B2 (hr) |
| EP (3) | EP2272850B1 (hr) |
| JP (4) | JP5057986B2 (hr) |
| KR (3) | KR101289998B1 (hr) |
| CN (2) | CN102993213A (hr) |
| AR (1) | AR052322A1 (hr) |
| AU (2) | AU2005300693B2 (hr) |
| BR (1) | BRPI0517689A (hr) |
| CA (1) | CA2584911C (hr) |
| CY (1) | CY1113059T1 (hr) |
| DK (1) | DK1812448T3 (hr) |
| EC (1) | ECSP12007431A (hr) |
| ES (1) | ES2388142T3 (hr) |
| GT (1) | GT200500311A (hr) |
| HK (2) | HK1211587A1 (hr) |
| HR (1) | HRP20120652T1 (hr) |
| IL (3) | IL182691A (hr) |
| JO (1) | JO2897B1 (hr) |
| MA (1) | MA29033B1 (hr) |
| MX (2) | MX2007005429A (hr) |
| MY (2) | MY147404A (hr) |
| NO (2) | NO338960B1 (hr) |
| NZ (3) | NZ588025A (hr) |
| PE (3) | PE20130377A1 (hr) |
| PL (1) | PL1812448T3 (hr) |
| PT (1) | PT1812448E (hr) |
| RU (2) | RU2394038C2 (hr) |
| SI (1) | SI1812448T1 (hr) |
| TN (1) | TNSN07165A1 (hr) |
| TW (4) | TWI433852B (hr) |
| WO (1) | WO2006048296A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101516339B (zh) * | 2006-08-16 | 2012-06-13 | 诺瓦提斯公司 | 制备高度结晶的治疗化合物的固体分散体的方法 |
| EP2327706A1 (en) * | 2009-11-30 | 2011-06-01 | Novartis AG | Polymorphous forms III and IV of N-benzoyl-staurosporine |
| KR20160008267A (ko) | 2014-07-14 | 2016-01-22 | 주식회사 윈스 | 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템 |
| EP3592749A1 (en) * | 2017-03-06 | 2020-01-15 | Teva Pharmaceutical Works Ltd. | Solid state forms of midostaurin |
| WO2019215759A1 (en) * | 2018-05-09 | 2019-11-14 | Alaparthi Lakshmi Prasad | An improved process for preparation of midostaurin |
| IT201900004729A1 (it) | 2019-03-29 | 2020-09-29 | Procos Spa | Processo per la preparazione di midostaurina ad elevato grado di purezza |
| WO2020261293A1 (en) * | 2019-06-24 | 2020-12-30 | Dr. Reddy's Laboratories Limited | Process for preparation of midostaurin |
| IT201900014346A1 (it) * | 2019-08-08 | 2021-02-08 | Procos Spa | Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo |
| IT202000004291A1 (it) | 2020-03-02 | 2021-09-02 | Indena Spa | Processo per la purificazione di alcaloidi indolo carbazolici |
| CN111393454A (zh) * | 2020-05-07 | 2020-07-10 | 奥锐特药业(天津)有限公司 | 米哚妥林的新晶型及其制备方法 |
| CN115124551B (zh) * | 2021-03-24 | 2024-04-30 | 奥锐特药业(天津)有限公司 | 一种高纯度米哚妥林的制备方法 |
| WO2023205504A1 (en) * | 2022-04-22 | 2023-10-26 | Rutgers, The State University Of New Jersey | Formulations and methods for treating epidermolysis bullosa simplex and related conditions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5373501A (en) * | 1976-12-11 | 1978-06-30 | Kitasato Inst | Novel antibiotics amm2282 and process for preparing same |
| JPS60185719A (ja) | 1984-03-06 | 1985-09-21 | Ajinomoto Co Inc | 抗腫瘍剤 |
| IL86632A0 (en) * | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5073633A (en) * | 1989-03-23 | 1991-12-17 | Bristol-Myers Company | BMY-41950 antitumor antibiotic |
| US5096330A (en) * | 1990-06-21 | 1992-03-17 | M-B-W Inc. | Pitch control mechanism for a surface finishing machine |
| JPH05247055A (ja) * | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
| JPH05247955A (ja) | 1992-03-06 | 1993-09-24 | Taisei Corp | 擁壁の施工方法 |
| EP0575955B1 (en) | 1992-06-22 | 1999-09-15 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing staurosporine derivatives |
| WO1995032975A1 (en) * | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents |
| JP4070810B2 (ja) | 1995-12-11 | 2008-04-02 | セファロン・インコーポレイテッド | タンパク質キナーゼｃの阻害剤としての縮合イソインドロン |
| EP1214336A1 (en) * | 1999-08-30 | 2002-06-19 | Universität Zürich | Synthesis of template-fixed beta-hairpin loop mimetics |
| AU2002304784A1 (en) | 2001-03-26 | 2002-10-08 | Novartis Pharma Gmbh | Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer |
| KR100407758B1 (ko) | 2001-08-27 | 2003-12-01 | 씨제이 주식회사 | 스타틴의 제조에 있어서 락톤화 방법 |
| US7608420B2 (en) * | 2003-04-22 | 2009-10-27 | Lonza Ag | Process for the recovery of staurosporine from a fermentation broth |
-
2005
- 2005-10-26 JO JO2005162A patent/JO2897B1/en active
- 2005-10-28 MY MYPI20055091A patent/MY147404A/en unknown
- 2005-10-28 GT GT200500311A patent/GT200500311A/es unknown
- 2005-10-28 MY MYPI20091911A patent/MY154878A/en unknown
- 2005-11-03 EP EP10173464.8A patent/EP2272850B1/en active Active
- 2005-11-03 PT PT05803350T patent/PT1812448E/pt unknown
- 2005-11-03 NZ NZ588025A patent/NZ588025A/en not_active IP Right Cessation
- 2005-11-03 KR KR1020127022584A patent/KR101289998B1/ko active IP Right Grant
- 2005-11-03 NZ NZ554653A patent/NZ554653A/en not_active IP Right Cessation
- 2005-11-03 DK DK05803350.7T patent/DK1812448T3/da active
- 2005-11-03 MX MX2007005429A patent/MX2007005429A/es active IP Right Grant
- 2005-11-03 RU RU2007120695/04A patent/RU2394038C2/ru active
- 2005-11-03 CA CA2584911A patent/CA2584911C/en active Active
- 2005-11-03 WO PCT/EP2005/011789 patent/WO2006048296A1/en active Application Filing
- 2005-11-03 KR KR1020077010191A patent/KR101333851B1/ko active IP Right Grant
- 2005-11-03 CN CN2012104320940A patent/CN102993213A/zh active Pending
- 2005-11-03 SI SI200531555T patent/SI1812448T1/sl unknown
- 2005-11-03 JP JP2007539535A patent/JP5057986B2/ja active Active
- 2005-11-03 EP EP15171908.5A patent/EP2955186A1/en not_active Withdrawn
- 2005-11-03 ES ES05803350T patent/ES2388142T3/es active Active
- 2005-11-03 PL PL05803350T patent/PL1812448T3/pl unknown
- 2005-11-03 KR KR1020127022582A patent/KR101265850B1/ko active IP Right Grant
- 2005-11-03 NZ NZ599033A patent/NZ599033A/xx not_active IP Right Cessation
- 2005-11-03 BR BRPI0517689-1A patent/BRPI0517689A/pt not_active IP Right Cessation
- 2005-11-03 US US11/718,029 patent/US8198435B2/en active Active
- 2005-11-03 MX MX2011007303A patent/MX346525B/es unknown
- 2005-11-03 CN CN2012101018747A patent/CN102627658A/zh active Pending
- 2005-11-03 AU AU2005300693A patent/AU2005300693B2/en active Active
- 2005-11-03 EP EP05803350A patent/EP1812448B1/en active Active
- 2005-11-04 TW TW094138677A patent/TWI433852B/zh not_active IP Right Cessation
- 2005-11-04 TW TW101122882A patent/TWI455941B/zh not_active IP Right Cessation
- 2005-11-04 TW TW103130302A patent/TWI530501B/zh not_active IP Right Cessation
- 2005-11-04 PE PE2012002519A patent/PE20130377A1/es not_active Application Discontinuation
- 2005-11-04 TW TW101122880A patent/TWI530500B/zh not_active IP Right Cessation
- 2005-11-04 PE PE2005001297A patent/PE20060947A1/es not_active Application Discontinuation
- 2005-11-04 AR ARP050104637A patent/AR052322A1/es not_active Application Discontinuation
- 2005-11-04 PE PE2009000199A patent/PE20090433A1/es not_active Application Discontinuation
-
2007
- 2007-04-19 IL IL182691A patent/IL182691A/en active IP Right Grant
- 2007-05-02 NO NO20072290A patent/NO338960B1/no unknown
- 2007-05-04 TN TNP2007000165A patent/TNSN07165A1/fr unknown
- 2007-05-22 MA MA29924A patent/MA29033B1/fr unknown
- 2007-12-19 HK HK15112508.3A patent/HK1211587A1/xx unknown
- 2007-12-19 HK HK07113889.0A patent/HK1108881A1/xx unknown
-
2009
- 2009-10-13 RU RU2009137788/04A patent/RU2467012C2/ru active
- 2009-12-07 AU AU2009245817A patent/AU2009245817B2/en active Active
-
2010
- 2010-08-19 IL IL207702A patent/IL207702A/en active IP Right Grant
-
2012
- 2012-01-16 IL IL217571A patent/IL217571A/en active IP Right Grant
- 2012-03-12 EC ECSP12007431 patent/ECSP12007431A/es unknown
- 2012-05-11 JP JP2012109447A patent/JP5701246B2/ja active Active
- 2012-05-15 US US13/472,130 patent/US8710216B2/en active Active
- 2012-08-10 HR HRP20120652TT patent/HRP20120652T1/hr unknown
- 2012-08-21 CY CY20121100747T patent/CY1113059T1/el unknown
-
2015
- 2015-01-09 JP JP2015003634A patent/JP2015063569A/ja not_active Withdrawn
-
2016
- 2016-07-12 NO NO20161152A patent/NO340404B1/no unknown
-
2017
- 2017-01-13 JP JP2017004320A patent/JP2017061578A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120652T1 (hr) | Organski spojevi | |
| Mathew et al. | Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors | |
| CZ303702B6 (cs) | Minocyklinové slouceniny | |
| CN101362718B (zh) | 4-(4-苯甲酰氨基苯氧基)-2-(甲基氨甲酰基)吡啶衍生物及其制备方法和用途 | |
| HRP20160246T4 (hr) | Dimaleat od aminokrotonilskog spoja i postupak njegove proizvodnje | |
| RU2008149242A (ru) | Малеатный сокристалл azd1152 | |
| Li et al. | Synthesis and evaluation of a novel series of heterocyclic oleanolic acid derivatives with anti-osteoclast formation activity | |
| CN103607888A (zh) | 取代的甲基甲酰基试剂以及使用所述试剂改进化合物的物理化学性质和/或药代动力学性质的方法 | |
| US20150072987A1 (en) | Novel compounds and therapeutic use thereof for protein kinase inhibition | |
| CN104109115A (zh) | 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途 | |
| WO2022107745A1 (ja) | Ｃｏｖｉｄ－１９の治療剤又は予防剤 | |
| WO2004005309A3 (en) | Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use | |
| CN103382195B (zh) | 苯并吡喃查尔酮类化合物及其制备方法和用途 | |
| JP2007515389A (ja) | テクトリゲニンのイソフラボン誘導体、その調製、および有効成分としてこれを含む抗ウィルス剤 | |
| JPH06501944A (ja) | Ｎ−（２−アルキル−３−メルカプトグルタリル）−アミノ−ジアザシクロアルカノン誘導体およびそれらのコラゲナーゼ抑制薬としての使用 | |
| CN108069954A (zh) | 含no供体的喹唑啉酮化合物 | |
| CN113336735B (zh) | 一种尿石素类化合物、制备方法、药物组合物及用途 | |
| CN108299255B (zh) | 组蛋白去乙酰化酶8选择性抑制剂及其制备方法和应用 | |
| ES2544327T3 (es) | Sales de amina de un derivado de carboestirilo útiles para el tratamiento de, entre otras, una úlcera gástrica | |
| CN102452986B (zh) | N-甲酰羟胺类化合物及其制备方法和用途 | |
| HRP20050831A2 (en) | Novel oxazole derivatives, their manufacture and use as pharmaceutical agents | |
| CA2105683C (en) | N-¬¬4,5-dihydroxy-and 4,5,8-trihydroxy-9,10-dihydro-9, 10-dioxo-2-anthracene-yl|carbonyl|amino acids useful in the therapy of osteoarticular affections | |
| US20030120073A1 (en) | Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases | |
| JPH06505229A (ja) | 抗ウイルス薬としてのチアゾロ−［２，３−ａ］−イソインドール誘導体の使用および新規なチアゾロ−［２，３−ａ］−イソインドール誘導体 | |
| CN102443005A (zh) | 查尔酮的螺杂环类化合物及其用途 |